Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood

Therapeutic Drug Monitoring

Volumn 34, Issue 2, 2012, Pages 222-226

  McMillin, Gwendolyn A ^a   Johnson Davis, Kamisha ^a   Dasgupta, Amitava ^b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Afinitor; Certican; everolimus; LC MS MS; Zortress

Indexed keywords

AMMONIA; CYCLOSPORIN A; EDETIC ACID; EVEROLIMUS; RAPAMYCIN; TACROLIMUS;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FILTRATION; HUMAN; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STANDARD; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; SIROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 84858698087     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318246d515     Document Type: Article

References (19)

1. Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy. 2010;30:1044-1056.
2. Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc. 2004;36(suppl 2):500S-503S. (Pubitemid 38373919)
3. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83-95. (Pubitemid 38283132)
4. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42. (Pubitemid 27327197)
5. Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three dosages on the incidence and severity of acute rejection. Transplantation. 2001;71:1400-1406. (Pubitemid 32507112)
6. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: pharmacokinetics, exposure response relationships and influence on cyclosporine. Clin Pharmacol Ther. 2001;69:48-56. (Pubitemid 32108671)
7. Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of everolimus in solid organ transplantation. Ther Drug Monit. 2005;27: 666-676. (Pubitemid 41437646)
8. Christians U, Jacobsen W, Serkova N, et al. Automated fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl. 2000:748:41-53.
9. Korecha M, Shaw LM. Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice. Ann Transplant. 2009;14:61-72.
10. Dasgupta A, Moreno V, Balark S, et al. Rapid estimation of whole blood everolimus concentrations using architect sirolimus assay and mathematical equations: comparison with everolimus values determined by liquid chromatography/mass spectrometry. J Clin Lab Anal. 2011;25: 207-211.
11. Baldelli S, Cippa A, Gabrieli R, et al. Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. Clin Biochem. 2006;39:1152-1159. (Pubitemid 44848323)
12. Sallustio BC, Noll BD, Morris RG. Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLCUV and immunoassay methods. Clin Biochem. 2011;44:231-236.
13. Moes DJ, Press RR, de Fijter JW, et al. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. Ther Drug Monit. 2010;32:413-419.
14. Salm P, Warnholtz C, Boyd J, et al. Evaluation of a fluorescence polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem. 2006;39:732-738. (Pubitemid 44036785)
15. Dasgupta A, Davis B, Chow L. Evaluation of QMS everolimus assay using Hitachi 917 analyzer: comparison with liquid chromatography/mass spectrometry. Ther Drug Monit. 2011;33:149-154.
16. Ivanova M, Artusi C, Polo G, et al. High throughput LC-MS/MS method for monitoring sirolimus and everolimus in the clinical routine clinical laboratory. Clin Chem Lab Med. 2011;49:1151-1158.
17. Koster RA, Dijkers EC, Uges DR. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. Ther Drug Monit. 2009;31: 116-125.
18. Ji M, Kim S, Chung HJ, et al. Evaluation of the MassTrak Immunosuppressant XE Kit for the determination of everolimus and cyclosporin A in human whole blood employing isotopically labeled internal standards. Clin Chem Lab Med. [published online ahead of print July 14, 2011] doi:10.1515/CCLM.2011.669.
19. Mueller DM, Rentsch KM. Sensitive quantification of sirolimus and everolimus by LC-MS/MS with online sample cleanup. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878: 1007-1012.